Fineline Cube

Follow:
14778 Articles
Novartis's Kisqali Approved by EC for Adjuvant Treatment of High-Risk Early Breast Cancer
CompanyDrug

Novartis’s Kisqali Approved by EC for Adjuvant Treatment of High-Risk Early Breast Cancer

Sanofi Launches Modulus, a Pioneering Manufacturing Facility in Singapore
Company

Sanofi Launches Modulus, a Pioneering Manufacturing Facility in Singapore

Chia Tai Tianqing's Benmelstobart Combo Approved by NMPA for Endometrial Cancer Treatment
CompanyDrug

Chia Tai Tianqing’s Benmelstobart Combo Approved by NMPA for Endometrial Cancer Treatment

Sichuan Kelun-Biotech's SKB264/MK-2870 Approved by NMPA for Triple Negative Breast Cancer
CompanyDrug

Sichuan Kelun-Biotech’s SKB264/MK-2870 Approved by NMPA for Triple Negative Breast Cancer

NHC Aims for Nationwide Inspection Result Sharing in Medical Consortia by 2030
Policy / Regulatory

NHC Aims for Nationwide Inspection Result Sharing in Medical Consortia by 2030

Ji Xing Pharmaceuticals' Varenicline Nasal Spray Gains NMPA Approval for Xerophthalmia
CompanyDrug

CORXEL’s Varenicline Nasal Spray Approved by NMPA for Dry Eye Treatment

Arrowhead and Sarepta Seal $11.38 Billion Global Licensing Deal for Rare Disease Treatments
CompanyDeals

Arrowhead and Sarepta Seal $11.38 Billion Global Licensing Deal for Rare Disease Treatments

Pfizer Partners with CR Pharma to Expand Cancer Drug Access in China
CompanyDrug

Pfizer Partners with CR Pharma to Expand Cancer Drug Access in China

Roche’s Evrysdi Receives Patent Term Extension in China, Extending Protection to 2035
Legal / IP

Roche’s Evrysdi Receives Patent Term Extension in China, Extending Protection to 2035

CanSino Biologics' Menhycia Vaccine Aims to Expand Age Range with NMPA Filing
CompanyDrug

CanSino Biologics’ Menhycia Vaccine Aims to Expand Age Range with NMPA Filing

Jiangsu Hengrui Medicine's SHR-1819 Receives NMPA Approval for Atopic Dermatitis Clinical Trial
CompanyDrug

Jiangsu Hengrui Medicine’s SHR-1819 Receives NMPA Approval for Atopic Dermatitis Clinical Trial

AstraZeneca's Truqap Meets Primary Endpoint in Phase III Prostate Cancer Study
CompanyDrug

AstraZeneca’s Truqap Meets Primary Endpoint in Phase III Prostate Cancer Study